NASHVILLE, Tenn. / Nov 20, 2023 / Business Wire / Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences:
BTIG 3rd Annual Ophthalmology Day
Format: Fireside Chat (Virtual)
Date/Time: Monday, November 27, 2023, at 1:30 p.m. ET
Piper Sandler 35th Annual Healthcare Conference (The Lotte New York Palace, New York, NY)
Format: Fireside Chat (In-Person)
Date/Time: Thursday, November 30, 2023, at 8:00 a.m. ET
Harrow management will be available for one-on-one meetings during both conferences. Investors interested in meeting with management should contact their BTIG or Piper Sandler representative to request a meeting.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$38.52 |
| Daily Change: | -0.52 -1.33 |
| Daily Volume: | 523,939 |
| Market Cap: | US$1.430B |
October 06, 2025 September 26, 2025 September 08, 2025 August 11, 2025 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load